glp-1 agonists side effects Effects: A Complete Guide to What You Can Expect GLP-1 Agonists - What is

Description

The number of beneficiaries eligible for the Medicare GLP-1 Bridge is unknown, but a previous KFF analysis estimated that close to 14 million Medicare beneficiaries had a diagnosis of overweight or obesity in 2020 (BMI of 25-29.9 and 30 or more, respectively), though applying the specific criteria that determine eligibility for the Medicare GLP-1 Bridge would reduce that number

Fatigue can show up early in treatment, during dose increases, or anytime your body is adjusting

Finally, another 48-week phase 2 study in subjects with hepatic steatosis but not T2D results in a mean weight loss of 25.9% compared to 0.1% for placebo (107)

Future research will probably include more patients with combined therapy, which will help to elucidate the timing and sequence of how these medications should be combined